By integrating RetinalGenix’s non-invasive retinal imaging platform with Seer Bio’s advanced proteomic profiling, RetinalGenix aims to uncover molecular and cellular signatures associated with disease ...

Significant gaps exist in HCPs' knowledge, attitudes, and practices regarding DR screening, particularly among non-ophthalmic professionals. Inadequate training, lack of screening tools, and high ...

MONDAY, Aug. 18, 2025 (HealthDay News) -- For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review ...

Boehringer Ingelheim has inked a deal with Palatin Technologies worth up to €280 million (about $327 million) biobucks with the aim of developing new retinal disease therapies. The German drugmaker ...

China’s leading artificial intelligence startup DeepSeek Ltd., which took the industry by storm earlier this year, was reportedly forced to delay the release of its upcoming R2 model after struggling ...

Please provide your email address to receive an email when new articles are posted on . Ford Medical will distribute AEYE-DS to U.S. pharmacies and non-acute centers. The system pairs with a retinal ...

A retrospective cohort study suggested that users of GLP-1 receptor agonists had a 7% higher incidence of new-onset diabetic retinopathy. In patients with existing diabetic retinopathy, use of GLP-1 ...

Some reassuring news for patients taking GLP-1 receptor agonists: Concerns that the drugs may cause retinopathy may be overblown. A new analysis of nearly 160,000 people with diabetes taking four ...

Rivian is preparing to start production of its R2 compact crossover soon and is currently setting up the assembly line. Meanwhile, a pilot line builds pre-production R2 vehicles for testing before ...

Survival models using EHR data predicted progression from NPDR or DME to PDR in type 2 diabetes patients. Key risk factors for progression included age, race, NPDR severity, and diabetic nephropathy.